Entering a new era in the management of tumor-associated involution.
Glaspy
John A
JA
Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California 90095, USA. jglaspy@mednet.ucla.edu
D014408:Biomarkers, Tumor / Q000032:analysis*; D002100:Cachexia / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016207:Cytokines / Q000032:analysis / Q000378:metabolism*; D003866:Depressive Disorder / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D005260:Female; D005544:Forecasting; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D008297:Male; D009369:Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D010380:Peer Review; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D014408:Biomarkers, Tumor; D016207:Cytokines; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha